Recent Updates — CATX
Perspective Therapeutics announced updated interim results from its ongoing Phase 1/2a clinical trial of [212Pb]VMT-α-NET, a radiopharmaceutical targeting somatostatin receptor subtype 2-expressing neuroendocrine tumors. Presented at the ESMO Congress 2026, data for Cohort 3 (6.0 mCi dose) showed an objective response rate of 50% and a disease control rate of 95%. Across all cohorts, progression-free survival was 72% at 18 months. The treatment was well-tolerated with no dose-limiting toxicities or serious adverse events related to the study medication. The company aims to complete Phase 3 site start-up preparations by year-end 2026 and expects to initiate a registrational trial in 2027 following an End-of-Phase 2 meeting with the FDA. Perspective Therapeutics is a radiopharmaceutical development company pioneering advanced systemic treatments for cancers.
The U.S. Food and Drug Administration granted Fast Track Designation for the development of [212Pb]PSV359 (PSV359) to treat adult patients with locally advanced unresectable and/or metastatic fibroblast activation protein-positive solitary fibrous tumors. This designation facilitates more frequent interactions with regulators and may allow for rolling review, Accelerated Approval, or Priority Review if applicable requirements are met. PSV359 is an investigational FAP-targeted alpha-particle therapy currently being evaluated in a Phase 1/2a study. Perspective Therapeutics operates as a radiopharmaceutical development company pioneering advanced treatments for cancers throughout the body.
On October 1, 2026, Perspective Therapeutics filed a Form 8-K to update its corporate presentation. The filing incorporates by reference Exhibit 99.1, which details the company's next-generation radiopharmaceutical programs targeting neuroendocrine tumors (VMT-α-NET), melanoma (VMT01), and advanced solid tumors (PSV359). The presentation outlines ongoing Phase 1/2a trials, preliminary anti-tumor activity, and a $45 billion+ addressable market. Perspective Therapeutics operates in the biotechnology sector, focusing on targeted oncology therapies using radiopharmaceuticals.
On September 14, 2026, Perspective Therapeutics announced a clinical collaboration and supply agreement with Merck to evaluate the targeted alpha-particle therapy [212Pb]PSV359 in combination with Keytruda (pembrolizumab) for FAP-α positive solid tumors. Under the terms of the agreement, Merck will provide pembrolizumab at no cost as part of an amendment to Perspective's ongoing Phase 1/2a study (NCT06710756), which has completed enrollment in its first three monotherapy dose cohorts. This strategic partnership aims to assess whether combining targeted radiopharmaceutical treatment with an immune checkpoint inhibitor can improve outcomes for patients with advanced solid tumors expressing fibroblast activation protein alpha. Perspective Therapeutics is a radiopharmaceutical development company pioneering advanced treatments for cancers throughout the body.
Perspective Therapeutics, Inc. reported financial results for the quarter ended June 30, 2026, posting a net loss of $26.8 million, or $0.22 per share, compared to a net loss of $21.5 million in the prior year period. Research and development expenses increased to $21.5 million from $16.6 million, while general and administrative expenses remained stable at $7.8 million. The company held approximately $237 million in cash, cash equivalents, and short-term investments as of June 30, 2026, which management believes is sufficient to fund operations into late 2027. Clinically, the company advanced its VMT-α-NET program toward a Phase 3 study in neuroendocrine tumors, with site activation targeted for year-end 2026 subject to regulatory feedback. Perspective Therapeutics operates as a radiopharmaceutical development company pioneering alpha-emitting treatments for cancers.